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ProliferationObjective: Idiopathic pulmonary ﬁbrosis (IPF) is a devastating disease characterized by epithelial cell injury,ﬁbro-
blast activation and excessive extracellular matrix deposition. Although protein arginine methyltransferase
1 (PRMT1) was found to regulate cell proliferation, differentiation and migration, its role in the development/
progression of IPF has not yet been described.
Results: Expression of PRMT1 was elevated in lung homogenates from IPF patients. Signiﬁcant upregulation of
PRMT1 expressionwas also observed in the lungs of bleomycin-treatedmice. Immunohistochemical analysis re-
vealed PRMT1-positive staining in ﬁbroblasts/myoﬁbroblasts and alveolar type II cells of IPF lungs and in ﬁbrotic
lesions of bleomycin-injured lungs. Fibroblasts isolated from IPF lungs demonstrated increased PRMT1 expres-
sion. Interleukin-4 (IL-4), a proﬁbrotic cytokine, enhanced the expression of PRMT1 and the migration of
donor and IPF ﬁbroblasts. Interference with the expression or the activity of PRMT1 diminished the migration
of the cells in response to IL-4. Strikingly, even though the incubation of donor and IPF ﬁbroblasts with IL-4 did
not affect their proliferation, depletion, but not blockage of PRMT1 activity suppressed cell growth.
Conclusions: PRMT1 can contribute to the development of pulmonary ﬁbrosis by regulating ﬁbroblast activities.
Thus, interference with its expression and/or activity may provide a novel therapeutic option for patients with IPF.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Idiopathic pulmonaryﬁbrosis (IPF) is a chronic, progressive interstitial
lung disease with a median survival time of less than three years follow-
ing diagnosis [1]. It is characterized by a histological pattern of usual inter-
stitial pneumonia (UIP) with ﬁbroblast foci consisting of activated,
collagen producing myoﬁbroblasts [2]. Although the fundamental mech-
anisms that initiate and propagate IPF have not yet been fully deﬁned, it is
believed that abnormal alveolar epithelial cell activation leads to theLF, bronchoalveolar lavageﬂuid;
M, Dulbecco's Modiﬁed Eagle's
e factor; HLF, human lung ﬁbro-
H, lactate dehydrogenase; MMP,
D, porphobilinogen deaminase;
tric dimethylarginine; proSP-C,
ard error of the mean; TBS, tris-
mistry, Faculty of Medicine,
richstrasse 24, 35392 Giessen,
iessen.de (D. Zakrzewicz).impairment of epithelial–mesenchymal crosstalk resulting in the accu-
mulation of ﬁbroblasts and extracellular matrix (ECM) proteins in the
lung [2,3].
A growing body of evidence suggests that inﬂammatory cells
recruited to the site of an injury might contribute to the ﬁbrotic process
through the production of proﬁbrotic cytokines such as interleukin (IL)-
4, IL-13 and transforming growth factor (TGF)-β [4]. In line with this
notion, elevated levels of IL-4 were measured in IPF bronchial alveolar
lavage ﬂuid (BALF) and an increased expression of the IL-4 and IL-13
receptors was detected in IPF lung ﬁbroblasts [5,6,7]. In addition, IL-4
deﬁcient mice or mice with targeted disruption of the key components
of the IL-4 signaling pathway were found to be protected against
pulmonary ﬁbrosis [8,9]. However, the anti-inﬂammatory therapies
based on broad immunosuppression have been unsuccessful, and
newly discovered pharmacotherapeutic options for IPF still remain
limited [10,11].
Protein arginine methylation is a posttranslational modiﬁcation
which is catalyzed by a family of intracellular enzymes termed protein
arginine methyltransferases (PRMT) [12]. In humans PRMTs have
been classiﬁed into type I (PRMT1, 2, 3, 4/CARM1, 6 and 8) and type II
(PRMT5, 7 and FBXO11) enzymes depending on their speciﬁc catalytic
2679D. Zakrzewicz et al. / Biochimica et Biophysica Acta 1852 (2015) 2678–2688activity [12]. Type I PRMTs catalyze the formation of asymmetric
dimethylarginine (ADMA), whereas type II PRMTs form symmetric
dimethylarginine (SDMA) [12,13]. PRMT1 is a predominant type I
PRMT in mammalian cells that is responsible for approximately 85% of
total protein arginine methylation [14]. Thus, PRMT1 is engaged inFig. 1. Expression of PRMT1 is upregulated in the lungs of IPF patients. (A) Lung homogenates o
expression of PRMT1 and PRMT4was analyzed. Representative donors (7/15) and patients (7/2
15 (donors), n = 25 (IPF patients); ***, p ≤ 0.001. (D) PRMT1 mRNA expression in lung tissue
expressed as ΔCt using PBGD as the reference gene. (E) IPF and donor lung tissue sections w
independent sections obtained from at least three different patients or donors. Selected areas
control was performed by omitting a primary antibody (I, II, III). Bar size 50 μm.various cellular processes including signal transduction, gene transcrip-
tion, DNA repair, and mRNA splicing [12]. Hence, dysregulated PRMT1
expression was found to contribute to the pathogenesis of a variety of
diseases including cardiovascular and pulmonary disorders [13,15]. In
our study, we sought to investigate whether dysregulated PRMT1btained from IPF patients and donors were subjected to Western blotting and the protein
5) are shown. β-actin served as a loading control. (B, C) Densitometry analysis of (A); n=
of donors (n = 5) and IPF patients (n = 6) was assessed by RT-qPCR. RT-qPCR results are
ere stained for PRMT1, α-SMA and proSP-C. Staining was performed on at least three
were magniﬁed (boxed areas). Arrowheads indicate PRMT1-positive ﬁbroblasts. Negative
2680 D. Zakrzewicz et al. / Biochimica et Biophysica Acta 1852 (2015) 2678–2688expression may regulate ﬁbroblast activities and thus contribute to the
development/progression of pulmonary ﬁbrosis.
2. Materials and methods
2.1. Study population
The investigations have been conducted in accordance with the
Declaration of Helsinki principles and were approved by the local
ethics committee. Informed consent was obtained from either theFig. 2. Pulmonary PRMT1 expression is enhanced in amousemodel of bleomycin-induced lung
treated mice at day 10, 14 and 18 post-application was assessed by RT-qPCR. RT-qPCR results a
protein expression in lung homogenates of control (saline 18d) and bleomycin-treated mice
challenged animals (3–5/7–9) are shown. (C) Densitometry analysis of (B); n = 7–9 mice
bleomycin-treated mice at day 18 post-application stained for PRMT1, proSP-C, α-SMA and C
proSP-C and CD68. Bar size 20 μm.patients or their next-of-kin. Lung tissue was obtained from 25 IPF
patients who underwent lung transplantation at the Department of
Cardiothoracic Surgery, Medical University of Vienna, Austria. IPF di-
agnosis was based on both clinical criteria as well as proof of a usual
interstitial pneumonia (UIP) pattern in histopathological specimens
from the explanted lungs [16]. Non-utilized donor lungs served as a
control (n = 15). Inﬂammatory processes were not observed in the
donor lungs following histopathological evaluation. For demograph-
ic and clinical characteristics of the patient cohort, please refer to
[17].ﬁbrosis. (A) PRMT1mRNA expression in lung tissue of control (saline 18d) and bleomycin-
re expressed as ΔCt using β-actin as the reference gene; n = 4–5 mice/group. (B) PRMT1
at day 10, 14 and 18 post-application. Representative control mice (3/7) and bleomycin-
/group; *, p ≤ 0.05. (D) Representative lung tissue sections from control (saline) and
D68. Arrowheads indicate cells that demonstrate a colocalization of PRMT1 with α-SMA,
2681D. Zakrzewicz et al. / Biochimica et Biophysica Acta 1852 (2015) 2678–26882.2. Bleomycin administration
Six-ten week old mice (C57BL/6 N) were used in all experiments.
Bleomycin (Almirall Prodesfarma, Barcelona, Spain) was applied by
microsprayer (Penn-Century Inc., Philadelphia, PA) as a single dose of
5 U/kg bw. Age and sex-matched controls received saline. At different
time points after bleomycin application, mice were euthanized with a
lethal dose of pentobarbital. The animals were kept in accordance
with NIH guidelines and the experiments were undertaken with the
permission of the local authorities.
2.3. Cell isolation
Primary human lung ﬁbroblasts (HLF) were isolated from donor
(n = 8) and IPF (n = 8) lungs as previously described [17].
2.4. Cell culture and cell stimulation
HLF were cultured in a 5% CO2 incubator at 37 °C in Dulbecco's
Modiﬁed Eagle's Medium (DMEM)/F12 (Invitrogen Life Technologies,
Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine
serum (FBS; Hyclone, Cramlington, UK) and 1% Penicillin/Streptomycin
(Invitrogen Life Technologies). Before stimulation with different concen-
trations of IL-4 (R&DSystemsGmbH,Wiesbaden, Germany), HLFwere in-
cubated overnight in serum-free DMEM/F12. Treatment of HLF with
10 μM AMI-1 (Sigma-Aldrich, Taufkirchen, Germany) was performed in
DMEM/F12 supplemented with 10% FBS.Fig. 3. Expression of PRMT1 is increased in IPF lung ﬁbroblasts. (A, B) PRMT1 (A) and PRMT4 (
assessed byRT-qPCR. RT-qPCR results are expressed asΔCt using PBGD as the reference gene; **,
donor and IPF lungs. β-actin served as a loading control. (D, E) Densitometry analysis of (C); n
PRMT1. DAPI was used to demonstrate the nuclei. Bar size 20 μm. (G) Semiquantitative analys2.5. Protein isolation and Western blotting
For details, please refer to the online supplement.
2.6. Immunocytochemistry/immunohistochemistry
Immunocytochemical and immunohistochemical analyses were
performed as previously described [17]. For details, please refer to the
online supplement.
2.7. Antisense oligonucleotides
Commercially available siRNA sequence directed against human
PRMT1 and a universal negative-control siRNA (both from Santa Cruz
Biotechnology, Santa Cruz, CA) were employed. Overnight serum-
starved cells were transfected with siRNA (100 nM) using the
siLentFect™ Lipid transfection reagent (Bio-Rad Laboratories GmbH,
Munich, Germany) in accordance with the manufacturer's instruction.
The siRNA-mediated downregulation of PRMT1 expression was assessed
12 h and 24 h post-transfection by real-time PCR (qPCR) and Western
blotting, respectively.
2.8. RNA isolation and RT-qPCR
RNA isolation and RT-qPCR were performed as previously described
[17]. Details are outlined in the online supplement.B) mRNA expression in ﬁbroblasts isolated from donor (n= 8) and IPF (n= 10) lungs as
p ≤ 0.01. (C) PRMT1 andPRMT4 protein expression inhuman lungﬁbroblasts isolated from
= 8; **, p ≤ 0.01. (F) Human lung ﬁbroblasts isolated from IPF and donor lungs stained for
is of (F); n ≥ 20; ***, p ≤ 0.001.
Fig. 4. IL-4 stimulates PRMT1 expression in a dose- and time-dependent manner in HLF. (A) Fibroblasts were isolated from human donor lungs and stimulated with different concentra-
tions of IL-4. After 24 h cell crude extracts were subjected to Western blotting. Representative Western blots are shown (n = 6). β-actin served as a loading control. (B) Human lung
ﬁbroblasts stimulated with 10 ng/ml IL-4 were harvested at indicated time points and subjected to Western blotting using an anti-PRMT1 antibody. Representative Western blots are
shown (n= 5). β-actin served as a loading control. (C, D) Densitometry analysis of (A) and (B), respectively; *, p ≤ 0.05. (E) Human lung ﬁbroblasts isolated from donor lungs, stimulated
with 10 ng/ml IL-4 for 36 h and stained for PRMT1. DAPI was used to demonstrate the nuclei. Bar size 20 μm. (F) Semiquantitative analysis of (E); n ≥ 20; ***, p ≤ 0.001. (G)Western blot
analysis of PRMT1 expression in donor and IPF lung ﬁbroblasts stimulated with IL-4 (10 ng/ml) for 36 h. β-actin served as a loading control. Ctrl, control.
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HLFwere transfected with PRMT1 or control siRNAs, or treated with
10 μM AMI-1 or 0.01% DMSO (vehicle control). After 24 h LDH release
into cell culture media was measured using a Cytotoxicity Detection
Kit (Roche Diagnostic Roche Applied Science, Mannheim, Germany) in
accordance with the manufacturer's instruction. HLF treated with 1%
Triton X-100 for 3 min served as a positive control.
2.10. Scratch wound-healing assay
Cells were seeded into 6-well tissue culture plates at a density of
1 × 106 cells/well and starved overnight. siRNA-transfected HLF, AMI-Fig. 5. PRMT1 knockdown inhibits IL-4-driven lung ﬁbroblastmigration. (A) Donor and IPF hum
against PRMT1 (siPRMT1). After 24 h cellswere stimulatedwith IL-4 (10 ng/ml) for 16 h and sub
from the scratchwound healing assay at time 0 h and 16h are shown. (B) The rate ofwound clos
Data representmean values± SEM, n=4; *, p b 0.05; **, p b 0.01; ***, p b 0.001. (C) Fibroblastsw
the transwell-ﬁlter membrane and allowed to invade the bottom side overnight. Representativ
(D) The invading cells were counted. Data represent mean values ± SEM, n = 3; *, p b 0.05. (
thymidine incorporation. Data represent mean values ± SEM; n = 3; *, p ≤ 0.05; **, p ≤ 0.01
and anti-ASYM24 antibodies. β-actin served as a loading control. Asterisks indicate reduction itreated cells and respective controls were stimulated with 10 ng/ml
IL-4. Twenty four hours after stimulation, HLF were seeded into silicone
inserts with a deﬁned cell-free gap (Ibidi, Planegg–Martinsried,
Germany). Images of the gap area were taken after removing the
inserts at 0 and 16 h. The rate of wound closure was assessed by
counting the cells that had migrated into the same-sized square
ﬁelds.2.11. Transwell-ﬁlter migration assay
A transwell-ﬁlter migration assay was performed as previously
described [18]. Further details are provided in the online supplement.an lung ﬁbroblasts were transfectedwith universal control siRNA (siUNC) or RNA directed
jected to a scratchwound healing assay in serum-free DMEM/F12. Representative pictures
urewas assessed by counting the cells that hadmigrated into the same-sized squareﬁelds.
ere transfectedwith siUNC or siPRMT1. After 24 h cells were plated onto the upper side of
e images of the cells on the underside of the transwell-ﬁlter membrane are demonstrated.
E) Proliferation of siUNC- and siPRMT1-transfected donor and IPF HLF as assessed by [3H]
. (F) Efﬁciency of PRMT1 knockdown as assessed by Western blotting using anti-PRMT1
n protein methylation. Untr., untreated.
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Proliferation of HLF was determined by a DNA synthesis assay based
on the uptake of [3H]thymidine (Amersham Biosciences, Freiburg,
Germany). Twenty four hours after transfection of HLF with siRNAs or
after overnight exposure of cells to AMI-1 and/or IL-4, the cells were
seeded onto a 48-well tissue culture plate. Subsequently, the cells
were pulsed with 1.2 μCi/ml [3H]thymidine. After 16 h, the cells were
solubilized in 0.5 M NaOH and [3H]thymidine incorporation was deter-
mined by liquid scintillation spectrometry.
2.13. Statistics
The statistical analyzewasperformedusingGraphPadPrism, version
5.02 forWindows (GraphPad Software, La Jolla, CA). Patient data are re-
ported as medians and interquartile ranges, and are shown in box plots
according to Tukey's deﬁnition. Differences between groups were
assessed using the Student's t-test or the Mann–Whitney U-test.
When three or more groups were compared, analysis of variance
(ANOVA) followed by Tukey's post hoc test was used. Experimental
data are presented as mean (±SEM). A p value of less than 0.05
was considered statistically signiﬁcant.
3. Results
3.1. PRMT1 expression is upregulated in IPF lungs
Initially, we investigated the expression of PRMT1 in the lung tissue
of IPF patients. While elevated PRMT1 protein expression was noted in
IPF lungs as compared to donor lungs (Fig. 1A, B), PRMT1 mRNA levels
remained unchanged (Fig. 1D). Since PRMT4 shares structural and func-
tional similarities with PRMT1 [19], we also analyzed the expression of
this enzyme in IPF lungs. However, no changes in PRMT4 protein levels
were observed (Fig. 1C). Immunohistochemical analysis of donor lung
sections demonstrated a PRMT1-positive staining in alveolar (Fig. 1E)
and bronchial (data not shown) epithelial cells. In IPF lungs, PRMT1
was associated with hyperplastic alveolar epithelial type II cells (ATII),
bronchial epithelial cells and ﬁbroblasts/myoﬁbroblasts in ﬁbrotic foci
(Fig. 1E).
3.2. PRMT1 expression is increased in the lungs of bleomycin-treated mice
Next, we investigated the expression of PRMT1 in the lungs of mice
exposed to bleomycin. Although the mRNA level of PRMT1 was not
changed in the lungs of affected animals (Fig. 2A), PRMT1 protein ex-
pression was upregulated at day 10 and 14 post-application (Fig. 2B,
C). Immunohistochemical inspection of bleomycin-challenged mouse
lungs revealed PRMT1- positive staining in monocyte/macrophages
(identiﬁed by CD68 staining), ATII (identiﬁed by proSP-C staining)
and myoﬁbroblasts (identiﬁed by α-SMA staining) suggesting that
PRMT1 is ubiquitously expressed in the injured lung (Fig. 2D).
3.3. IPF ﬁbroblasts are characterized by increased PRMT1 expression
As ﬁbroblasts are key effector cells in the development of ﬁbrosis [2],
we focused further studies on the role of PRMT1 in the regulation ofFig. 6. Inhibition of PRMT activity blocks IL-4-induced lung ﬁbroblast migration. (A) Primary h
with IL-4 (10 ng/ml) for 16 h and subjected to a scratch wound healing assay in serum-free DM
shown. (B) The rate of wound closure was assessed by counting the cells that had migrated i
**, p ≤ 0.01. (C) Fibroblasts were pretreated overnight with DMSO or 10 μM AMI-1. Afterwards
to invade the bottom side overnight. Representative images of cells on the underside of the tra
resent mean values ± SEM, n = 3; *, p ≤ 0.05. (E) Proliferation of untreated and AMI-1 (10 μM
SEM, n = 3. Data represent mean values ± SEM; n = 3; *, p ≤ 0.05. (F) Efﬁciency of PRMT1 inh
loading control. Asterisks indicate reduction in protein methylation. Untr., untreated.various processes in this cell population. First, we sought to characterize
PRMT1 and PRMT4 expression inﬁbroblasts isolated from IPF anddonor
lungs. IPF HLF demonstrated enhanced PRMT1mRNA (Fig. 3A) and pro-
tein expression (Fig. 3C, D) as compared to donor HLF. In contrast, no
changes in PRMT4 mRNA (Fig. 3B) and protein (Fig. 3C, E) levels were
observed. Immunocytochemical analysis veriﬁed augmented PRMT1
expression in IPF HLF and revealed a predominant localization of
PRMT1 in the nucleus and a moderate PRMT1 abundance in the cyto-
plasm (Fig. 3F). Analysis of the immunostaining intensity conﬁrmed in-
creased PRMT1 expression in IPF HLF when compared to donor cells
(Fig. 3G).3.4. IL-4 stimulates PRMT1 expression in human lung ﬁbroblasts
As previous studies demonstrated the induction of PRMT1 expres-
sion following stimulation of lung adenocarcinoma cells with IL-4 [20],
we next investigated whether exposure of HLF to this proﬁbrotic
cytokine regulates PRMT1 synthesis. Treatment of donor HLF with IL-4
stimulated PRMT1 protein expression in a dose- and time-dependent
manner (Fig. 4A–D). The maximal PRMT1 expression was achieved
within 24 h of stimulation (Fig. 4D). Immunocytochemical analysis
also revealed enhanced PRMT1 staining in HLF exposed for 24 h to IL-
4 when compared to unstimulated cells (Fig. 4E). Analysis of the immu-
nostaining intensity validated these results (Fig. 4F). An increase in
PRMT1 protein expression was also observed when IPF ﬁbroblasts
were exposed to IL-4 (Fig. 4G).3.5. IL-4-induced PRMT1 expression regulates donor and IPF ﬁbroblast
motility
IPF is a devastating disease that is characterized by an excessive pro-
liferation and migration of parenchymal ﬁbroblasts [2]. Thus, in further
studies we evaluated the importance of altered PRMT1 expression for
motility of HLF. A scratch wound healing assay revealed the increased
migration of IPF HLF as compared to donor HLF (Fig. 5A, B). The addition
of IL-4 enhanced themigration of both cell types (Fig. 5A, B). The deple-
tion of PRMT1 reduced themotility of unstimulated and IL-4-stimulated
donor and IPF HLF; the latter to the level observed in the cells isolated
from donor lungs (Fig. 5A, B). Similar effects were observed when the
transwell ﬁlter migration assay was applied (Fig. 5C, D). Here, a clear
tendency towards a reduction of PRMT1-depleted HLF migration
under basal conditions and upon IL-4 stimulation was observed (Fig.
5C, D). Furthermore, although PRMT1knockdownof donor HLF resulted
in downregulation of the expression of proﬁbrotic genes such as Col1a1
andMMP-2, (Supplementary Fig. 1A), it did not have any effect on the
MMP-2 and MMP-9 activities (Supplementary Fig. 1B). The expression
of Col3a1 was not inﬂuenced by PRMT1 knockdown (Supplementary
Fig. 1A). Strikingly, even though the incubation of HLF with IL-4 did
not affect donor and IPF HLF proliferation, the depletion of PRMT1 sig-
niﬁcantly reduced cell growth (Fig. 5E). PRMT1 knockdown neither
changed cell morphology nor altered cell survival (Supplementary Fig.
2A, B, respectively). The efﬁciency of PRMT1 knockdown was assessed
by RT-qPCR (Supplementary Fig. 1A) and Western blotting using an
anti-ASYM24 antibody which recognizes asymmetrically methylated
proteins (Fig. 5F). Altogether, these results demonstrate the pivotaluman lung ﬁbroblasts were pretreated with DMSO or 10 μM AMI-1. Cells were stimulated
EM/F12. Representative pictures from the wound healing assay at time 0 h and 16 h are
nto the same-sized square ﬁelds. Data represent mean values ± SEM, n = 4; *, p ≤ 0.05;
, the cells were plated onto the upper side of the transwell-ﬁlter membrane and allowed
nswell-ﬁlter membrane are demonstrated. (D) The invading cells were counted. Data rep-
)-treated HLF as assessed by [3H]thymidine incorporation. Data represent mean values ±
ibition as assessed byWestern blotting using anti-ASYM24 antibodies. β-actin served as a
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and upon exposure to IL-4.
3.6. Catalytic activity of PRMT controls IL-4-triggered donor and IPF
ﬁbroblast migration
To evaluate whether PRMT activity is involved in the regulation of
IL-4-induced lung ﬁbroblast migration, an inhibitor of PRMT, AMI-1,
was utilized [20,21]. Although, AMI-1 interacts with the substrate-
binding pocket of the enzymes, and thus inhibits total activity of
PRMTs [22], the IC50 value of AMI-1 towards PRMT1 is 20 times lower
than towards PRMT4 (8.8 μM versus 169.8 μM, respectively) [22]. A
scratch wound healing assay revealed an increased migration of IPF
HLF as compared to donor HLF (Fig. 6A, B). Treatment of donor and
IPF HLF with AMI-1 attenuated themigration of cells under basal condi-
tions and upon exposure to IL-4. (Fig. 6A, B). Moreover, as depicted in
Fig. 6C and D, AMI-1 treatment reduced motility of unstimulated
donor and IPF HLF and IL-4-stimulated donor HLF in a transwell
migration assay. The inhibition of PRMT activity neither altered
the expression of PRMT1, Col1a1, Col3a1 and MMP-2 (Supplementa-
ry Fig. 3A) nor inﬂuencedMMP-2 andMMP-9 activities (Supplementary
Fig. 3B). Furthermore, AMI-1 treatment did not affect HLF proliferation,
supporting the notion that PRMT activity is required for cell migration
but dispensable for cell growth (Fig. 6E). Importantly, the incubation of
HLF with AMI-1 did not change their morphology (Supplementary
Fig. 4A) and did not induce LDH release (Supplementary Fig. 4B).
The efﬁcacy of AMI-1 was demonstrated by Western blot analysis
using the anti-ASYM24 antibody (Fig. 6F). Collectively, our results
imply that interference with PRMT1 activity reduces the motility
of HLF, but does inﬂuence their growth.
4. Discussion
In our present study we sought to investigate the role of PRMT1
in the pathogenesis of IPF. PRMT1 expression was found to be signif-
icantly enhanced in the lungs of IPF patients when compared to con-
trols. PRMT1 was localized in IPF lungs to bronchial and alveolar
epithelial cells, as well as to ﬁbroblasts/myoﬁbroblasts present in ﬁ-
brotic foci. Using the mouse model of bleomycin-induced pul-
monary ﬁbrosis, we demonstrated a time-dependent increase of
PRMT1 protein expression in the lungs of affected animals. Further-
more, we identiﬁed IL-4 as a trigger of enhanced PRMT1 expression
in HLF. Finally, we showed, for the ﬁrst time, that the interference
with PRMT1 expression and/or activity may decrease the IL-4-
driven migratory properties of donor and IPF HLF. Altogether, our
results imply that PRMT1 may play an important role in the devel-
opment/progression of IPF.
The ﬁbrotic processes that occur in the lungs of IPF patients are the
result of a recurrent injury to the alveolar epithelium followed by an
uncontrolled proliferation of ﬁbroblasts [2]. However, a large body of
evidence suggests that IPF might be a neoproliferative disorder since it
exhibits several pathogenic features similar to cancer including epige-
netic and genetic abnormalities, abnormal activation of speciﬁc signal
transduction pathways, and dysregulated proliferation of the cells
[23]. A number of studies point out a fundamental role of protein argi-
nine methylation and PRMT1 in the aforementioned processes and
thus in the pathobiology of various types of human cancer including
lung carcinoma [15]. While the causative role of PRMTs has already
been extensively studied in lung cancer pathogenesis, little is known
about the involvement of PRMTs in the development of chronic
ﬁbroproliferative lung disorders, in particular IPF. PRMT1 is highly
expressed in the lung tissue as compared to other organs [24], and it ac-
counts for the bulk of total protein arginine methylation in mammalian
cells [14]. Hence, any dysregulation of PRMT1 expression and/or activity
may have a great impact on lung homeostasis [13]. Abnormal PRMT1
expression has recently been implicated in the pathogenesis of asthmaand pulmonary hypertension by inﬂuencing the eosinophil inﬁltration
of the airways [20] and hypoxia-inducible factor (HIF)-dependent re-
sponses, respectively [25]. Our study demonstrates, for the ﬁrst time,
that PRMT1 protein expression is enhanced in IPF lungs and that this
may have potential consequences for the migratory properties of the
cells. Although no change in the PRMT1mRNA level in IPF lung homog-
enates was observed, a clear alteration of PRMT1mRNA expression was
visible in the ﬁbroblasts isolated from diseased lungs. This suggests that
PRMT1 mRNA levels may vary among different types of lung cells.
Furthermore, the increased PRMT1 mRNA level detected in isolated
IPF HLF and upon stimulation of the cells with IL-4 can be a result of
either enhanced PRMT1 promotor activity or altered PRMT1 mRNA
stability. In this regard, it was demonstrated that IL-4, on the one
hand, stabilizes 15-lipoxygenase-1 mRNA in human orbital ﬁbroblasts
[26], and, on the other, regulates promotor activity of the IL-13 receptor
α2 in theHaCaT human keratinocyte cell line [27]. Moreover, studies by
Seegmuller et al. revealed that IL-4 may simultaneously modulate
promotor activity and mRNA stability, thereby inﬂuencing overall
mRNA levels in the cell [28]. Yet, further studies focusing on the molec-
ular mechanism of the IL-4-triggered upregulation of PRMT1 mRNA
level in HLF are pending.
Although IL-4 levels were found to be increased in BALF of IPF
patients, its proﬁbrotic properties have not yet been entirely deﬁned
[4]. Here, we demonstrate that IL-4 by enhancing the expression of
PRMT1 can modulate the migratory properties of human lung ﬁbro-
blasts and thereby contribute to the pathogenesis of pulmonary ﬁbrosis.
Albeit, IPF is considered a disease of disturbed epithelial–mesenchymal
crosstalk, recent studies have drawn attention to the role of inﬂamma-
tory cells in the pathobiology of this disorder [4]. It has been postulated,
for example, that T-lymphocyte andmast cellsmay contribute to the de-
velopment of pulmonary ﬁbrosis by producing a number of pro-ﬁbrotic
mediators such as tryptase, TGF-β and IL-4 [29,30]. All the aforemen-
tioned molecules have pleiotropic properties with biological effects on
a variety of target cells including B and T lymphocytes, macrophages,
hematopoietic cells, mast cells, and ﬁbroblasts [4,29]. In this regard, it
has been demonstrated that IL-4 is a powerful inducer of TGF-β1 ex-
pression leading thereby to increased extracellular matrix synthesis
[31] and thus to enhanced movement of pulmonary ﬁbroblasts [32]. In
line with these ﬁndings we observed the augmented migration of HLF
in response to IL-4. Interestingly, the pro-migratory properties of HLF
were abolished by either depletion of PRMT1 or treatment of the cells
with the inhibitor of PRMT activity, AMI-1. As PRMT1 knockdown de-
creased HLF proliferation possibly by the mechanism involving its abil-
ity to regulate telomere length and/or stability and thus induce growth
arrest [33], we cannot exclude that this effect could, in part, account for
the reduction in IL-4-driven cell migration [34]. Furthermore, PRMT1-
controlled changes in ECM and ECM-associated proteins might also
have an inﬂuence on the observed alteration in cell migration. Our re-
sults point towards the involvement of PRMT1 in the modulation of
Col1a1 and MMP-2 mRNA expression. In this respect, the direct effect
of PRMT1 on the regulation of MMP-2 transcription and its capability
to serve as a co-activator of the nuclear factor-κB (NF-κB) and thus as
a regulator of MMP-2 expression have already been described [35,36].
Moreover, the ability of PRMT1 to methylate histones provides the
possibility for its direct participation in the epigenetic regulation of
gene transcription [12]. Methylation of the arginine 3 at histone H4 by
PRMT1 [12,37] is largely considered as a mark of transcriptionally acti-
vated genes [37,38].
The inhibitory effect of AMI-1 on IL-4-induced HLF migration dif-
fered substantially from that observed when PRMT1 was depleted.
AMI-1 treatment did not alter cell proliferation and mRNA levels of
Col1a1, Col3a1 andMMP-2, but clearly inﬂuenced intracellular protein
argininemethylation thereby inhibiting IL-4-induced ﬁbroblasts migra-
tion. In line with this supposition, the blockage of PRMT1-dependent
methylation of the transcription factor Twist1 attenuated cell migration
of A549 lung epithelial cell line [39]. Furthermore, PRMT1-mediated
2687D. Zakrzewicz et al. / Biochimica et Biophysica Acta 1852 (2015) 2678–2688methylation of nuclear factor of activated T cells cofactor protein NIP45
was found to be essential for the synthesis and release of IL-4 from T-
lymphocytes [40], suggesting the involvement of PRMT1 in the IL-4 pro-
duction and in the IL-4-driven cellular effects. Thus, it is tempting to
speculate that the imbalance in cellular protein arginine methyla-
tion (“protein methylome”) manifested by disturbed chromatin re-
modeling and dysregulated function of a number of nuclear and
cytoplasmic non-histone proteins culminated in uncontrolled ﬁbro-
blast behavior.
In conclusions, our study provides compelling evidence that PRMT1
drives proliferation andmigration of human lung ﬁbroblasts and thereby
links intracellular protein arginine methylation to ﬁbrogenic processes.
Thus, we present novel rational for strategies aimed at blocking PRMT1
in IPF.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.09.008.
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